ALS awareness. New Research Grants

November 2011
PN;Nov2011, Vol. 65 Issue 11, p21
Trade Publication
The article focuses on the 20 new research grants in laboratories from the Amyotrophic Lateral Sclerosis (ALS) Association which focuses on the contribution of the new genes TDP43 and FUS to ALS, immune mechanisms in ALS, and development of Riluzole (Rilutek) derivatives with enhanced activity.


Related Articles

  • Support services important component of Rilutek launch. Rodgers, Katie // Drug Topics;2/5/96, Vol. 140 Issue 3, p46 

    Reports on the planned launch of Rhone-Poulenc Rhorer's (RPR) Rilutek riluzole drug for amyotrophic lateral sclerosis (ALS). Patient support services; Background information; Implications; Plans and expectations.

  • Understanding Lou Gehrig's disease.  // Patient Care;2/28/1997, Vol. 31 Issue 4, p16 

    Reports on the nationwide program to develop guidelines for the treatment of amyotyhrophic lateral sclerosis (ALS) in the United States. Prevalence of ALS in the country; Contact information for physicians and patients interested to participate in the program.

  • A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. Bensimon, G.; Lacomblez, L.; Meininger, V. // New England Journal of Medicine;3/3/94, Vol. 330 Issue 9, p585 

    Background: Amyotrophic lateral sclerosis is a progressive motor neuron disease for which there is no adequate treatment. Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis. Methods: To evaluate the efficacy and safety of the...

  • ALS drug slows progression. Rodgers, Katie // Drug Topics;11/20/95, Vol. 139 Issue 22, p52 

    Reports on the findings of a phase III clinical trial presented at the SiSixt International Symposium on amyotrophic lateral sclerosis.motor neuron disease.

  • Nerve preserver. Munson, Marty; Higbee, Beth // Prevention;Nov95, Vol. 47 Issue 11, p58 

    Reports on the results of a pilot study on a drug used for staving off the crippling effects of Lou Gehrig's disease or amyotrophic lateral sclerosis published in the March 3, 1994 issue of the `New England Journal of Medicine'. Possibility of a prolonged survival; Availability of other...

  • Update on amyotrophic lateral sclerosis. R.M.D. // Cortlandt Forum;11/25/96, Vol. 9 Issue 11, p121 

    Responds to an inquiry regarding recommended treatment for amyotrophic lateral sclerosis.

  • ALS guidelines.  // Drug Topics;12/9/96, Vol. 140 Issue 23, p32 

    Reports on the creation of the Amyotrophic Lateral Sclerosis Clinical Assessment, Research and Education (CARE) Program to study practice patterns and treatment guidelines. Funding from Rhone-Poulenc Rorer; Goal of improving treatment and quality of life of patients.

  • Combination approach may be key to Lou Gehrig's disease. Henahan, Sean // Drug Topics;5/6/96, Vol. 140 Issue 9, p78 

    Reports that a combination of three putative pathways of the pathogenesis of amyotrophic lateral sclerosis is provided researchers with promising therapeutic strategies for the disease, also known as Lou Gehrig's Disease. Causes of neural degeneration; Therapeutic properties of riluzole and...

  • Case & Comment. Pennachio, Dorothy L. // Patient Care;2/28/2002, Vol. 36 Issue 4, p47 

    Comments on case reports in medicine as of February 2002. Details on a patient diagnosed with vasculitis; Symptoms and causes of the disease; Treatment on a patient with amyotrophic lateral sclerosis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics